Nektar Therapeutics (NKTR) Other Non-Current Liabilities (2010 - 2026)

Nektar Therapeutics' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 25.01% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (up 25.01% YoY), while the FY2025 annual figure was $8.6 million, up 19.11% from the prior year.
• Other Non-Current Liabilities was $8.4 million for Q1 2026 at Nektar Therapeutics, down from $8.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $8.6 million in Q4 2025 to a low of $2.1 million in Q2 2022.
• Historically, Other Non-Current Liabilities has averaged $5.9 million across 5 years, with a median of $6.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities plunged 85.72% in 2022, then surged 147.64% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $7.6 million in 2022, then slumped by 38.62% to $4.6 million in 2023, then jumped by 56.22% to $7.2 million in 2024, then climbed by 19.11% to $8.6 million in 2025, then fell by 2.08% to $8.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $8.4 million (Q1 2026), $8.6 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.